Express Scripts (ESRX) Price Target Raised to $87.00

Express Scripts (NASDAQ:ESRX) had its target price upped by Maxim Group from $78.00 to $87.00 in a research note issued to investors on Thursday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the stock.

ESRX has been the subject of several other research reports. Jefferies Group set a $72.00 target price on Express Scripts and gave the stock a buy rating in a research report on Tuesday, August 29th. Robert W. Baird reiterated a hold rating and set a $56.00 target price on shares of Express Scripts in a research report on Friday, September 1st. ValuEngine cut Express Scripts from a buy rating to a hold rating in a research report on Friday, September 1st. Royal Bank of Canada assumed coverage on Express Scripts in a research report on Tuesday, September 19th. They set a sector perform rating and a $68.00 target price for the company. Finally, UBS cut Express Scripts from a market perform rating to an underperform rating in a report on Monday, October 9th. Five research analysts have rated the stock with a sell rating, ten have given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $74.40.

Shares of Express Scripts (ESRX) traded up $2.53 during trading hours on Thursday, hitting $71.55. The stock had a trading volume of 8,786,136 shares, compared to its average volume of 4,094,484. The company has a market capitalization of $40,523.99, a P/E ratio of 10.46, a P/E/G ratio of 1.06 and a beta of 0.88. The company has a debt-to-equity ratio of 0.86, a quick ratio of 0.61 and a current ratio of 0.73. Express Scripts has a 1 year low of $55.80 and a 1 year high of $73.42.

Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.90 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.90. Express Scripts had a return on equity of 25.46% and a net margin of 3.64%. The firm had revenue of $24.68 billion for the quarter, compared to the consensus estimate of $25.68 billion. During the same period in the prior year, the company posted $1.74 earnings per share. The company’s quarterly revenue was down 2.9% on a year-over-year basis. sell-side analysts expect that Express Scripts will post 7.02 EPS for the current year.

In other Express Scripts news, VP Phyllis S. Anderson sold 643 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $62.37, for a total transaction of $40,103.91. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Timothy C. Wentworth acquired 8,000 shares of the company’s stock in a transaction on Tuesday, October 31st. The shares were purchased at an average cost of $61.13 per share, for a total transaction of $489,040.00. Following the acquisition, the chief executive officer now owns 98,628 shares of the company’s stock, valued at approximately $6,029,129.64. The disclosure for this purchase can be found here. 0.68% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ESRX. Nordea Investment Management AB raised its position in shares of Express Scripts by 1.4% during the 2nd quarter. Nordea Investment Management AB now owns 7,116,445 shares of the company’s stock worth $454,314,000 after purchasing an additional 97,953 shares during the last quarter. Van ECK Associates Corp grew its stake in shares of Express Scripts by 5.1% during the 3rd quarter. Van ECK Associates Corp now owns 506,511 shares of the company’s stock valued at $32,072,000 after buying an additional 24,728 shares during the period. First Trust Advisors LP grew its stake in shares of Express Scripts by 25.3% during the 2nd quarter. First Trust Advisors LP now owns 708,955 shares of the company’s stock valued at $45,260,000 after buying an additional 143,163 shares during the period. Lazard Asset Management LLC grew its stake in shares of Express Scripts by 81.8% during the 2nd quarter. Lazard Asset Management LLC now owns 112,666 shares of the company’s stock valued at $7,192,000 after buying an additional 50,707 shares during the period. Finally, Victory Capital Management Inc. grew its stake in shares of Express Scripts by 12.5% during the 3rd quarter. Victory Capital Management Inc. now owns 35,421 shares of the company’s stock valued at $2,243,000 after buying an additional 3,940 shares during the period. 88.44% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://ledgergazette.com/2017/12/17/express-scripts-esrx-price-target-raised-to-87-00.html.

Express Scripts Company Profile

Express Scripts, Inc is a pharmacy benefit management (PBM) company in North America, offering a range of services to its clients, which include health insurers, third-party administrators, employers, union-sponsored benefit plans, workers’ compensation plans and government health programs. It operates in two segments: PBM and Emerging Markets (EM).

Analyst Recommendations for Express Scripts (NASDAQ:ESRX)

Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply